Estrella Immunopharma, Inc. (NASDAQ: ESLA; ESLAW) Receives Buy Rating with a 12-Month Price Target of $16.00 from D. Boral Capital
Portfolio Pulse from
Estrella Immunopharma, Inc. (NASDAQ: ESLA; ESLAW) has received a Buy rating from D. Boral Capital with a 12-month price target of $16.00. The company is developing T-cell therapies for cancer and autoimmune diseases.
February 19, 2025 | 10:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Estrella Immunopharma has been rated a Buy by D. Boral Capital with a 12-month price target of $16.00, indicating positive market sentiment and potential stock price increase.
The Buy rating and price target from a reputable investment bank like D. Boral Capital suggests confidence in Estrella's future performance, likely leading to increased investor interest and a potential rise in stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100